The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centre
GSK’s Arexvy has become the first vaccine for respiratory syncytial virus (RSV) to be approved in the EU, getting the nod from the European Commission for use in older adu
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th
An FDA advisory committee has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine for use in expectant mothers, potentially opening up a niche for the shot, where
GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrat
GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human m
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho